Phase 1 study of KHK7580

A single-dose phase 1 study of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222486

Enrollment

Registered

2014-05-14

Start date

2014-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism in patients receiving peritoneal dialysis

Interventions

investigational material(s) Generic name etc : KHK7580 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Written informed consent - Stable chronic renal disease patients receiving peritoneal dialysis for at least 16 weeks prior to the screening - intact PTH value >= 240 pg/mL at the screening

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety Number and types of adverse events, laboratory tests, vital signs and electrocardiogram	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026